Literature DB >> 35299628

Generalized EEG Slowing Across Phasic REM Sleep, Not Subjective RBD Severity, Predicts Neurodegeneration in Idiopathic RBD.

Si-Yi Gong1, Yun Shen1, Han-Ying Gu1, Sheng Zhuang1, Xiang Fu1,2, Qiao-Jun Wang1, Cheng-Jie Mao1, Hua Hu1, Yong-Ping Dai1, Chun-Feng Liu1,2,3.   

Abstract

Purpose: Idiopathic rapid eye movement sleep behavior disorder (iRBD) is the prodromal marker of α-synuclein degeneration with markedly high predictive value. We aim to evaluate the value of electroencephalography (EEG) data during rapid eye movement (REM) sleep and subjective RBD severity in predicting the conversion to neurodegenerative diseases in iRBD patients.
Methods: At the baseline, iRBD patients underwent clinical assessment and video-polysomnography (PSG). Relative spectral power for nine frequency bands during phasic and tonic REM sleep in three regions of interest, slow-to-fast ratios, clinical and PSG variables were estimated and compared between iRBD patients who converted to neurodegenerative diseases (iRBD-C) and iRBD patients who remained disease-free (iRBD-NC). Receiver operating characteristic (ROC) curves evaluated the predictive performance of slow-to-fast ratios, and subjective RBD severity as assessed with RBD Questionnaire-Hong Kong.
Results: Twenty-two (33.8%) patients eventually developed neurodegenerative diseases. The iRBD-C group showed shorter total sleep time (p < 0.001), lower stage 2 sleep percentage (p = 0.044), more periodic leg-movement-related arousal index (p = 0.004), increased tonic chin electromyelographic activity (p = 0.040) and higher REM density in the third REM episode (p = 0.034) than the iRBD-NC group. EEG spectral power analyses revealed that iRBD phenoconverters showed significantly higher delta and lower alpha power, especially in central and occipital regions during the phasic REM state compared to the iRBD-NC group. Significantly higher slow-to-fast ratios were observed in a more generalized way during the phasic state in the iRBD-C group compared to the iRBD-NC group. ROC analyses of the slowing ratio in occipital areas during phasic REM sleep yielded an area under the curve of 0.749 (p = 0.001), while no significant predictive value of subjective RBD severity was observed.
Conclusion: Our study shows that EEG slowing, especially in a more generalized manner during the phasic period, may be a promising marker in predicting phenoconversion in iRBD, rather than subjective RBD severity.
© 2022 Gong et al.

Entities:  

Keywords:  EEG slowing; RBD severity; idiopathic rapid eye movement sleep behavior disorder; neurodegenerative diseases; neuroprotective therapy; phenoconversion

Year:  2022        PMID: 35299628      PMCID: PMC8923684          DOI: 10.2147/NSS.S354063

Source DB:  PubMed          Journal:  Nat Sci Sleep        ISSN: 1179-1608


  67 in total

1.  EEG spectral power analysis of phasic and tonic REM sleep in young and older male subjects.

Authors: 
Journal:  J Sleep Res       Date:  1993-03       Impact factor: 3.981

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Slowing of electroencephalogram in rapid eye movement sleep behavior disorder.

Authors:  Maria Livia Fantini; Jean-François Gagnon; Dominique Petit; Sylvie Rompré; Anne Décary; Julie Carrier; Jacques Montplaisir
Journal:  Ann Neurol       Date:  2003-06       Impact factor: 10.422

Review 4.  MDS clinical diagnostic criteria for Parkinson's disease.

Authors:  Ronald B Postuma; Daniela Berg; Matthew Stern; Werner Poewe; C Warren Olanow; Wolfgang Oertel; José Obeso; Kenneth Marek; Irene Litvan; Anthony E Lang; Glenda Halliday; Christopher G Goetz; Thomas Gasser; Bruno Dubois; Piu Chan; Bastiaan R Bloem; Charles H Adler; Günther Deuschl
Journal:  Mov Disord       Date:  2015-10       Impact factor: 10.338

5.  Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort.

Authors:  Brit Mollenhauer; Ellen Trautmann; Friederike Sixel-Döring; Tamara Wicke; Jens Ebentheuer; Martina Schaumburg; Elisabeth Lang; Niels K Focke; Kishore R Kumar; Katja Lohmann; Christine Klein; Michael G Schlossmacher; Ralf Kohnen; Tim Friede; Claudia Trenkwalder
Journal:  Neurology       Date:  2013-08-30       Impact factor: 9.910

6.  Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series.

Authors:  Carlos H Schenck; Bradley F Boeve; Mark W Mahowald
Journal:  Sleep Med       Date:  2013-01-22       Impact factor: 3.492

7.  Abnormal activation of motor cortical network during phasic REM sleep in idiopathic REM sleep behavior disorder.

Authors:  Jun-Sang Sunwoo; Kwang Su Cha; Jung-Ick Byun; Tae-Joon Kim; Jin-Sun Jun; Jung-Ah Lim; Soon-Tae Lee; Keun-Hwa Jung; Kyung-Il Park; Kon Chu; Han-Joon Kim; Manho Kim; Sang Kun Lee; Kyung Hwan Kim; Carlos H Schenck; Ki-Young Jung
Journal:  Sleep       Date:  2019-02-01       Impact factor: 5.849

8.  Formation and suppression of acoustic memories during human sleep.

Authors:  Thomas Andrillon; Daniel Pressnitzer; Damien Léger; Sid Kouider
Journal:  Nat Commun       Date:  2017-08-08       Impact factor: 14.919

9.  Analysis of Sleep Macrostructure in Patients Diagnosed with Parkinson's Disease.

Authors:  Justa Elizabeth González-Naranjo; Maydelin Alfonso-Alfonso; Daymet Grass-Fernandez; Lilia María Morales-Chacón; Ivón Pedroso-Ibáñez; Yordanka Ricardo-de la Fe; Arnoldo Padrón-Sánchez
Journal:  Behav Sci (Basel)       Date:  2019-01-08

10.  Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients.

Authors:  Alex Iranzo; Ana Fernández-Arcos; Eduard Tolosa; Mónica Serradell; José Luis Molinuevo; Francesc Valldeoriola; Ellen Gelpi; Isabel Vilaseca; Raquel Sánchez-Valle; Albert Lladó; Carles Gaig; Joan Santamaría
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.